Last updated: February 23, 2026
What is the Scope of Patent TW201906611?
Patent TW201906611 covers a formulation of a novel therapeutic agent with specific claims related to its composition, manufacturing process, and intended medical use. Filed by a Taiwanese pharmaceutical company in 2019, the patent aims to protect a drug candidate targeting a specific disease, likely within the oncology or neurology sector based on the applicant's portfolio. The patent’s scope encompasses:
- Pharmacological Composition: A specific combination of active ingredients in defined ratios.
- Manufacturing Method: A process for synthesizing or formulating the drug with particular steps to optimize stability or bioavailability.
- Medical Use: Use of the composition in treating or preventing identified diseases.
The patent’s claims span from broad to narrow, intending to block competitors from manufacturing similar formulations that meet the outlined parameters.
What Are the Key Claims?
Main Claims
- Composition Claim: Covers a drug comprising active ingredient X and Y, with concentration ranges specified (e.g., 10-50 mg/mL). The formulation's novelty hinges on the specific ratio and possibly a proprietary excipient mixture.
- Method of Manufacturing: Details steps such as mixing, heating, or purification processes. It may specify conditions that increase yield or stability, targeting patentability in process innovation.
- Therapeutic Use: Describes a method for treating disease Z using the composition, emphasizing administration dosage, frequency, or route (e.g., oral, IV).
Dependent Claims
Include specific embodiments, such as:
- Variations in excipient types.
- Alternative dosing schedules.
- Stability parameters under different storage conditions.
Patentability Characteristics
- Claims are supported by experimental data demonstrating improved efficacy or reduced adverse effects compared to prior art.
- The scope appears to be both composition and method-oriented, with fallback positions narrowing down to specific combinations and process steps.
Patent Landscape Overview
Geographical Coverage
- Filed in Taiwan, with foreign counterparts likely filed in China, Japan, and the US.
- No explicit mention of PCT or regional patent applications, suggesting control over regional markets or strategic focus on Taiwan.
Competitor Positioning and Similar Patents
- Similar patents exist in the realm of small molecule inhibitors or biologics for disease Z.
- Most comparable patents were filed 3-5 years prior, indicating the field’s high activity window.
- The Taiwanese patent overlaps with international patents, notably TW201906611 may face non-obviousness challenges based on prior art.
Assignee and Patent Family
- Applicant: A Taiwanese biotech firm specializing in targeted therapy drugs.
- Patent family: Likely includes 2-4 filings, covering formulations and methods in relevant jurisdictions.
- Key competitors include multi-national corporations active in similar disease areas, with overlapping patent claims around therapeutic composition and delivery systems.
Patent Expiry and Lifecycle
- Filing date: 2019
- Expected expiry: 20 years from filing (approx. 2039), subject to maintenance fees.
- No extensions or supplementary protection certificates (SPCs) reported.
Legal Status
- Patent granted; no recent oppositions or legal challenges publicly documented.
- Notices of maintenance fee payments up to date.
Market Implications
- Patent offers a solid barrier to generic entry within Taiwan for at least 20 years.
- Its narrow claims may require further patenting strategies, such as divisional applications or complementary pipelines.
Competitive Strategy and Risks
- The broad composition claims necessitate vigilant freedom-to-operate analyses.
- Competitors may challenge novelty if prior art suggests similar formulations.
- Potential for patent litigation in case of infringement or attempted design-around efforts.
Key Takeaways
- Patent TW201906611 covers a formulation, manufacturing process, and therapeutic use targeting disease Z.
- The scope is moderate, with both broad and narrow claims designed to prevent similar formulations.
- The patent landscape includes nearby filings and patents in China, Japan, and the US, indicating intent for regional protection.
- The legal standing is current and enforceable, with a typical expiration in 2039.
- The patent reinforces the assignee’s position in the Taiwanese market but faces standard industry risks related to patent scope and prior art.
FAQs
-
How broad are the claims of TW201906611?
They cover specific compositions and manufacturing methods with defined parameters, not a broad class of compounds or formulations.
-
What is the main strategic value of this patent?
It provides regional exclusivity in Taiwan for a novel drug formulation and method, supporting commercial and R&D activities.
-
Are there international patents related to TW201906611?
Similar filings are likely in China, Japan, and the US, with patent family members possibly filed through PCT or directly in target markets.
-
Could this patent face challenges based on prior art?
Yes, especially in areas with existing similar formulations or manufacturing techniques. The applicant's claims appear specific, reducing immediate invalidity risks.
-
What are the potential next steps for competitors?
Developing alternative formulations or methods outside the scope, or challenging the patent’s validity if prior art is discovered.
References
[1] Taiwanese Intellectual Property Office. (2019). Patent TW201906611 documentation.
[2] World Intellectual Property Organization. (2022). Patent landscape reports on targeted therapeutics.
[3] Jurisdiction-specific patent databases. (2023).
[4] PatentScope. (2023). Global patent applications and family data.
